Genmab — Juli 2024

Solsen

https://investors.abbvie.com/static-files/c9936258-3a4c-48f0-968b-6d533ead6dee p7. If we take 3 month “revenue” data 14+22=36 then I belive real Epkinly revenue could be 31+32=63 (US+RW=Total) and the souce could right. My estimate is 45% of US revenue as collaboration revenu and Japan 8 mln out of the 22 mln recorded by Abbvie. If its true Genmab should record $38-40 mln in Q2 as Epkinly revenue. But hope we somewhere will get the revenue figures more easy

E_L

you have to start dialing a Danish phone number now if
you want Trial Information on PRO1184 https://www.clinicaltrials.gov/study/NCT05579366?tab=history&a=16&b=17#version-content-panel

E_L

AbbVie (ABBV) Q2 2024 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2024/07/25/abbvie-abbv-q2-2024-earnings-call-transcript/

E_L

" we continue to be pleased with the prescription trends for Epkinly in DLBCL. Commercialization is now underway for Epkinly's second indication, follicular lymphoma, in the U.S.

with European approval expected later this year."

E_L

"
In the area of hematologic oncology, we received accelerated approval in the U.S. for Epkinly as a monotherapy treatment for patients with relapsed/refractory follicular lymphoma after two or more lines of prior therapy. Epkinly is now the only T-cell-engaging bispecific approved in the U.S.

to treat both follicular lymphoma and diffuse large B-cell lymphoma. We're extremely excited to bring this new subcutaneous treatment option to patients suffering from follicular lymphoma.

E_L

We also recently received positive CHMP opinion with an approval decision in Europe expected later this year"

E_L

@Solsen medwatch corrected following your analysis
https://medwatch.dk/Medicinal___Biotek/article17305159.ece

gentogen

Det er vel fortsat forkert at hævde, at tallene er salgstal (?). Abbvie oplyser ikke salgstallene, men kun deres eget revenue

gentogen

I øvrigt antager jeg, at de 63 blot er halvårssummen af kvartalerne med 27 og de 36

E_L

correct

JKY_VH

Jep fra MW "(Korrektion: Tidligere opgjorte salgstal for andet kvartal på 63 mio. dollar var for første halvår)

Genmab kan se salget af kræftbehandlingen Epkinly gå yderligere frem i andet kvartal.

I andet kvartal nåede salget af Epkinly 36 mio. dollar, viser regnskabet fra den amerikanske medicinalkoncern Abbvie.

Dermed fortsætter fremgangen efter at salget i første kvartal nåede 27 mio. dollar og 17 mio. dollar i fjerde kvartal."

E_L

EMA Recommends extensions of therapeutic indication for Rybrevant (MARIPOSA 2)

E_L

Scope: “ Extension of indication to include amivantamab in combination with carboplatin
and pemetrexed for the treatment of adult patients with advanced non-small cell lung
cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions or Exon 21
L858R substitution mutations after failure of prior therapy including a third-generation EGFR
tyrosine kinase inhibitor (TKI) for RYBREVANT

Helge_LarsenPI-redaktør

Godmorgen

bibob

God morgen.

bibob

Er Trump ved at lave en “ Putin “ her ?? https://www.washingtonpost.com/elections/2024/07/26/2024-election-campaign-updates-harris-trump/

NiklasZ

Hvad har det med Genmab at gøre?

bibob

Intet og alt. Aktiemarkeder kan ikke lide diktatorer.

Darvin

Enig bibob - han er en af de farligste personer overhovedet ift demokrati og godverdensorden. Det har alt med Genmab og andre investeringer at gøre.

NiklasZ

Aktiemarkedet steg 36% i Trumps periode og økonomiske tiltag gav høj vækst i USA. Der blev kun startet en handelskrig, men ellers var der fredligt under hans periode. Det er igen ligesom de sidst to valg, et valg mellem pest eller kolera.